S3 Week 4 Pharmacology

Front 1

Types of therapy for each stage of COPD:

Back 1

Front 2

Classes of medication for treatment of COPD:

Back 2

Never give a LABA alone as monotherapy for long term control!

Front 3

Short acting B2 agonist:

Back 3

Front 4

Anticholinergic agents:

Back 4

Front 5

Systemic corticosteroids:

Back 5

Front 6

Corticosteroids for long term treatment; MOA:

Back 6

Front 7

Indications for corticosteroid use in long term control:

Back 7

Inhaled corticosteroids do not have the systemic effects that systemic corticosteroids do + they are delivered in a much, much smaller dose.

Front 8

Benefits of inhaled corticosteroids:

Back 8

- Inhaled Corticosteroids Prevent Death
- THE most effective long term medication for the control of asthma
- Useful in every treatment step of persistent asthma
- Reduces patient impairment and risk
- Preferred long term control medication in adults and in children of all ages

Front 9

Corticosteroid potencies:

Back 9

The more potent agents only have to be given one puff once per day.

Front 10

Adverse effects of corticosteroids:

Back 10

Front 11

Bioavailability of corticosteroids:

Back 11

Increased bioavailability causes increased systemic absorption. So you want an agent with LOW bioavailability.

Front 12

Back 12

Front 13

Mast cell stabilizer indications:

Back 13

Front 14

Adverse effects of mast cell stabilizer:

Back 14

Front 15

Spiriva:

Back 15

Front 16

Long acting B-agonist MOA:

Back 16

Front 17

LABA indications;

Back 17

Front 18

LABA products:

Back 18

Front 19

LABA/ICS combinations:

Back 19

Front 20

Leukotriene modifiers MOA:

Back 20

Front 21

Leukotriene modifiers indications:

Back 21

LIs are indicated for long term control and prevention of symptoms in all types of persistent asthma. No evidence that LIs are more effective than inahled steroids. LIs are not superior to LABA/inhaled steroid combinations. LI should be used as add on therapy or in place of steroids or LABA when those drugs are not tolerated.

Front 22

Adverse effects of leukotriene modifiers:

Back 22

Front 23

Methylxanthine MOA:

Back 23

Front 24

Methylxanthine Indications:

Back 24

A systemic drug with systemic side effects with multiple drug interactions. Regular blood testing is required. This is why this is not a preferred drug.

Front 25

Methylxanthine interactions:

Back 25

Front 26

Methylxanthine adverse effects:

Back 26

Front 27

Immunomodulators MOA:

Back 27

Front 28

Immunomodulator indications:

Back 28

Front 29

Immunomodulator warning:

Back 29

Front 30

Immunomodulator Adverse effects:

Back 30

Front 31

Inhaler Types:

Back 31

Front 32

Agents used to treat interstitial lung disease:

Back 32

Front 33

Treatment of ILD with corticosteroids:

Back 33

Front 34

Corticosteroid adverse effects:

Back 34

Front 35

Treatment for insterstitial lung disease

Back 35

Front 36

Treatment for interstitial lung disease

Back 36

Front 37

Immunosupressants for the treatment of interstitial lung disease:

Back 37

- May be used in conjunction with low dose corticosteroids
- These modalities require 8-12 week trial for a fair assessment of benefit
- Increased risk for infection
- Advise patient and watch carefully for signs of infection
- Increased risk for malignancies

* Cyclosporine and axathioprine

Front 38

Treatment for interstitial lung disease

Back 38

Front 39

Treatment for interstitial lung disease

Back 39

Front 40

Treatment for interstitial lung disease

Back 40

Front 41

Monitoring of cyclosporine:

Back 41

Front 42

Treatment for interstitial lung disease

Back 42

Front 43

Treatment for interstitial lung disease

Back 43

Front 44

Treatment for interstitial lung disease

Back 44

Front 45

Treatment for interstitial lung disease

Back 45

Front 46

Treatment for interstitial lung disease

Back 46

Front 47

For treatment of interstitial lung disease

Back 47